Furthermore, our findings support the idea that the induction of mitochondrial biogenesis, for instance by activating the SIRT1-and/or AMPK-dependent PGC-1α axis, or other mitochondriogenic pathways, could be a rational and potentially effective approach in the therapy of mitochondrial diseases. Here, PPARGC1A is linked to mitochondrial disease.